ArticleHepatology (Baltimore, Md.)2017
Elevated FABP1 serum levels are associated with poorer survival in acetaminophen-induced acute liver failure.
Article in Hepatology (Baltimore, Md.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 69 citations in OpenAlex.
- Critical care hepatology: A narrative review of current concepts and management.World journal of critical care medicine · 2026Review
- Large-Scale Plasma Proteomics Reveals Preclinical Biomarkers of Incident Severe Liver Disease.Proteomics. Clinical applications · 2026Article
- L-FABP as a Potential Biomolecular Marker of Liver Graft Injury.Journal of clinical medicine · 2025Article
- From fructose to the future: liver disease biomarkers and their prognostic value in acute liver failure.Critical reviews in clinical laboratory sciences · 2025Review
- Evaluation of Serum L-FABP as a Biomarker and Hepatoprotective Effect of L-FABP Using Wild-Type and Human L-FABP Chromosome Transgenic Mice.Journal of the American Association for Laboratory Animal Science : JAALAS · 2025Article
- Alpha-fetoprotein and carbohydrate antigen 19-9 as prognostic biomarkers in acute liver failure: A retrospective study.The Journal of international medical research · 2025Article
- Early acetaminophen Use and 90-day mortality in ICU patients with ischemic stroke.Frontiers in pharmacology · 2025Article
- The potential value of fatty acid binding protein 1 in Chronic HBV-related liver disease progression assessment.BMC infectious diseases · 2024Article
- Acute liver failure: A practical update.JHEP reports : innovation in hepatology · 2024Review
- Radiomics features based on dual-area CT predict the expression levels of fatty acid binding protein 4 and outcome in hepatocellular carcinoma.Abdominal radiology (New York) · 2024Article
- Fatty-Acid-Binding Proteins: From Lipid Transporters to Disease Biomarkers.Biomolecules · 2023Review
- Macrophage pathology in hepatotoxicity.Journal of toxicologic pathology · 2023Review
- [Acute Liver Failure: Current Updates and Management].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2023Review
- Drug-induced liver injury: a comprehensive review.Therapeutic advances in gastroenterology · 2023Review
- Unraveling the effect of intra- and intercellular processes on acetaminophen-induced liver injury.NPJ systems biology and applications · 2022Article
- Management of Acute Liver Failure: Update 2022.Seminars in liver disease · 2022Article
- Proteomics Indicates Lactate Dehydrogenase Is Prognostic in Acetaminophen-Induced Acute Liver Failure Patients and Reveals Altered Signaling Pathways.Toxicological sciences : an official journal of the Society of Toxicology · 2022Article
- Association between liver-type fatty acid-binding protein and hyperuricemia before and after laparoscopic sleeve gastrectomy.Frontiers in endocrinology · 2022Article
- Clinical and Neurologic Outcomes in Acetaminophen-Induced Acute Liver Failure: A 21-Year Multicenter Cohort Study.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2021Article
- Pathophysiological and diagnostic importance of fatty acid-binding protein 1 in heart failure with preserved ejection fraction.Scientific reports · 2021Article
Corrections and comments
- Commented on byREPLY.2017
- Commented on by
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
Abstract
Acetaminophen (APAP)-induced acute liver failure (ALF) is associated with significant mortality. Traditional prognostic scores lack sensitivity. Serum liver-type fatty acid binding protein (FABP1) early (day 1) or late (day 3-5) levels are associated with 21-day mortality in the absence of liver transplant. Serum samples from 198 APAP-ALF patients (nested case-control study with 99 survivors, 99 nonsurvivors) were analyzed by enzyme-linked immunosorbent assay with clinical data from the US Acute Liver Failure Study Group registry (1998-2014). APAP-ALF survivors had significantly lower serum FABP1 levels early (238.6 versus 690.8 ng/mL, P < 0.0001) and late (148.4 versus 612.3 ng/mL, P < 0.0001) compared with nonsurvivors. FABP1 > 350 ng/mL was associated with significantly higher risk of death at early (P = 0.0004) and late (P < 0.0001) time points. Increased serum FABP1 early (log FABP1 odds ratio = 1.31, P = 0.027) and late (log FABP1 odds ratio = 1.50, P = 0.005) were associated with significantly increased 21-day mortality after adjusting for significant covariates (Model for End-Stage Liver Disease, vasopressor use). Areas under the receiver operating characteristic curve for early and late multivariable models were 0.778 and 0.907, respectively. The area under the receiver operating characteristic curve of the King's College criteria (early, 0.552 alone, 0.711 with FABP1; late, 0.604 alone, 0.797 with FABP1) and the Acute Liver Failure Study Group prognostic index (early, 0.686 alone, 0.766 with FABP1; late, 0.711 alone, 0.815 with FABP1) significantly improved with the addition of FABP1 (P < 0.002 for all).
conclusionIn patients with APAP-ALF, FABP1 may have good potential to discriminate survivors from nonsurvivors and may improve models currently used in clinical practice; validation of FABP1 as a clinical prediction tool in APAP-ALF warrants further investigation. (Hepatology 2017;65:938-949).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.